Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 10 of 10 publications.
Skip to main content
Donohue IF, Bollu VK, Stull DE, Nelson LM, Williams VS, Stensland MD, Hanania NA. Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial. Int J Chron Obstruct Pulmon Dis. 2018 Feb 5;13:499-508.
Glaser DA, Hebert AA, Fehnel S, DiBenedetti D, Nelson L, Drew J, Pariser DM. The axillary sweating daily diary: a validated patient-reported outcome measure to assess axillary hyperhidrosis symptom severity. Poster presented at the 2017 Maui Derm for Dermatologists; March 2017. Maui, HI.
Donohue JF, Ganapathy V, Bollu V, Stensland MD, Nelson LM. Health status of patients with moderate to severe COPD after treatment with nebulized arformoterol tartrate or placebo for 1 year. Clin Ther. 2017 Jan;39(1):66-74. doi: 10.1016/j.clinthera.2016.11.021
Donohue J, Ganapathy V, Davenport E, Nelson L, Zhao X. COPD-related hospitalizations associated with arformoterol tartrate treatment among patients receiving concomitant tiotropium (TIO) therapy: post hoc analyses from a 52-week randomized, controlled study. Poster presented at the CHEST 2016 Annual Meeting; October 24, 2016. Los Angeles, CA. [abstract] Chest. 2016 Oct; 150(4_S). doi: 10.1016/j.chest.2016.08.990
Donohue J, Ganapathy V, Nelson L, Zhou X. Health-related quality of life among patients who experienced prior COPD-related exacerbations: post hoc analysis of a 52-week randomized placebo-controlled trial of nebulized arformoterol tartrate. Poster presented at the 2016 American Thoracic Society Annual Conference; May 18, 2016. San Francisco, CA.
Donohue J, Ganapathy V, Zhou X, Nelson L. Chronic obstructive pulmonary disease (COPD)-related hospitalizations by health status response among patients receiving arformoterol tartrate or placebo: post hoc analyses from a 52-week randomized, controlled study. Poster presented at the 2016 American Thoracic Society Annual Conference; May 15, 2016. San Francisco, CA.
Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials. Poster presented at the 15th Annual Caribbean Dermatology Symposium; January 26, 2016. Grand Cayman. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials. Poster presented at the 12th Annual Maui Derm for Dermatologists 2016 Conference; January 25, 2016. Maui, HI. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials. Poster presented at the Winter Clinical Dermatology Conference; January 15, 2016. Kauai, HI. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Lee LJ, Nelson LM, McLeod LD, Hill CD, Sweeney CT. Effects of insulin therapy on the Diabetes Symptom Checklist-Revised (DSC-R): data from a large insulin clinical trial. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 21, 2009. [abstract] Value Health. 12(3):A105.